Q-omics provides the consensus-scored R3HDM4 profile across patient tissues and cancer cell-line models. R3HDM4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, R3HDM4 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, R3HDM4 RNA expression shows 19,172 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where R3HDM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for R3HDM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes R3HDM4 survival associations across molecular data types. R3HDM4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible R3HDM4 RNA expression–survival associations across cancer types. High R3HDM4 expression shows unfavorable associations in ACC, KICH, KIRC and KIRP, but favorable associations in UCEC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for R3HDM4 RNA expression.
This table summarizes R3HDM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for R3HDM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. R3HDM4 shows higher tumor expression in COAD, LIHC, STAD, THCA, KIRP and READ. The COAD box plot shows higher R3HDM4 RNA expression in tumor versus normal tissue (log2 FC = +0.929, t-test p < 0.001).
This table shows molecular features associated with R3HDM4 in patient tissues and cancer cell lines. In patient samples, R3HDM4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, R3HDM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
